Short communicationEO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group
References (12)
- et al.
Mitomycin C analogues 1. Indoloquinones as potential bisalkylating agents
Tetrahedron
(1987) - et al.
Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung cancer cell lines
Int J Radiat Oncol Biol Phys
(1994) - et al.
Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression
Biochem Pharmacol
(1994) - et al.
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour toxicity in preclinical models
Eur J Cancer
(1993) - et al.
Cyclopropamitosenes: novel bioreductive anticancer agents—mechanisms of action and enzymatic reduction
Anti-Cancer Drugs
(1994) - et al.
Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase
Br J Cancer
(1995)
Cited by (52)
Advances on structure-activity relationship of NQO1-targeting antitumor quinones
2012, Chinese Journal of Natural MedicinesThe orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations
2012, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :Based upon its favorable preclinical activity, apaziquone was selected for clinical evaluation and formulated for intravenous administration [4]. However, no clinical responses were documented in the subsequent phase II clinical trials [6,7]. Most probably, the rapid elimination [5] and relatively poor penetration of the drug compromised drug delivery to tumors following systemic administration [16].
Bioreductive Drugs: from Concept to Clinic
2007, Clinical OncologyCitation Excerpt :Initial phase I studies of the synthetic MMC analogue EO9 showed no bone marrow toxicity and rapid clearance of EO9; the most important toxicity was proteinuria [173,174]. Phase II studies confirmed the toxicity findings, but the drug did not have any activity as a single agent in a range of tumour types [175,176]. This underlines the need to carry out combination studies when trialling a bioreductive drug.
Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer
2007, Journal of Pharmaceutical and Biomedical Analysis